Furthermore, administration of 25-HC-containing nanovesicles effectively inhibited SREBP2 activity and reduced pro-inflammatory cytokines in COVID-19 patient derived immune cells (Kim et al., 2021). This evidence concerns the gene SREBF2 and COVID-19.